<DOC>
	<DOCNO>NCT02563327</DOCNO>
	<brief_summary>The Tuberculosis Trials Consortium ( TBTC ) phase 3 treatment trial , Study 31 , investigate efficacy safety daily rifapentine ( 1200 mg daily ) without moxifloxacin part multidrug treatment regimens drug-sensitive pulmonary TB . The propose study ( Study 31 PK/PD ) examine population pharmacokinetics pharmacodynamics ( PK/PD ) high-dose daily rifapentine without moxifloxacin give 17 week . Two different PK sampling procedure require population PK/PD assessments involve rifapentine moxifloxacin : ( 1 ) intensive sample 6 samples/participant one occasion plus subsequent sparse sample subset Study 31 participant invite co-enroll Study 31 PK/PD ; ( 2 ) sparse sample 2-3 samples/participant Study 31 trial participant ( data collect part Study 31 treatment protocol ) . Herein , describe PK sampling conduct among Study 31 participant co-enrolled Study 31 PK/PD ( n=60 ) . Intensive PK sampling need participant estimate population PK model parameter bias satisfactory precision ( relative standard error &lt; 20 % ) . PK outcomes data participant Study 31 merge build population PK/PD model evaluate PK/PD parameter . Details regard plan analysis also provide Study 31 PK/PD protocol . Primary Objectives : 1 . Characterize population pharmacokinetics rifapentine 25-desacetyl rifapentine , use sparse PK data Study 31 intensive PK data Study 31 PK/PD . Using population PK model , determine post-hoc Bayesian estimate individual-level PK parameter . 2 . Examine relationship rifapentine PK parameters interest treatment efficacy . PK parameter include area concentration time curve ( AUC0-24 ) , peak concentration ( Cmax ) , time mean inhibitory concentration ( MIC ) , AUC/MIC . The treatment outcome interest time culture conversion time treatment failure relapse . Secondary Objectives : 3 . Among Study 31 participant lowest 10 % rifapentine AUC0-24 , examine PK/PD effect culture conversion sputum completion 4 month daily rifapentine therapy . 4 . Examine relationship safety outcome ( Grade 3 high adverse event ) rifapentine PK parameter ( AUC0-24 , Cmax , AUC0-24/MIC time MIC ) . 5 . Characterize population PK moxifloxacin , estimate moxifloxacin AUC0-24 Cmax moxifloxacin administer rifapentine give daily dose 1200 mg. 6 . Examine relationship moxifloxacin PK treatment outcome ( describe objective 2 rifapentine ) moxifloxacin PK safety ( described objective 4 rifapentine ) . Design : In Study 31 PK/PD , among 60 participant tuberculosis enrol rifapentine-based treatment arm Study 31 , PK data collect two occasion . At TBTC sit capacity perform activity , participant 6 schedule PK sample per participant collect measure rifapentine ( without moxifloxacin ) concentration approximately 24 hour . In addition among 60 participant , 2 3 schedule PK sample obtain second `` late '' sample &gt; 14 day first PK sampling .</brief_summary>
	<brief_title>Pharmacokinetic Pharmacodynamic Study High-Dose Rifapentine Moxifloxacin Treatment Tuberculosis</brief_title>
	<detailed_description>RIFAPENTINE Rifapentine approve United States Food Drug Administration treatment drug-susceptible pulmonary TB base open-label prospective randomize phase 3 study 722 participant pulmonary TB . Rifapentine long half-life rifampin , drug inhibit bacterial RNA synthesis bind β-subunit DNA-dependent RNA polymerase . Rifapentine Pharmacokinetics With once-weekly treatment participant pulmonary TB , mean plasma AUC0-inf 296 , 410 , 477 μg*h/mL 600 , 900 , 1200 mg dos administer without food , Cmax 12 , 15 , 19 μg/mL . The bioavailability rifapentine 70 % healthy adult volunteer give single 600-mg dose . Food ( total , 850 calorie 33 g protein , 55 g fat , 58 g carbohydrate ) increase AUC0-inf 43 % Cmax 44 % compare fasting condition . Rifapentine 25-desacetyl metabolite 98 % 93 % protein-bound serum , primarily albumin . Rifapentine metabolize 25-desacetyl rifapentine esterase enzyme present liver blood . The half-life rifapentine 14 17 hour half-life 25-desacetyl rifapentine 13 hour . Rifapentine excrete bile eliminate feces , &lt; 10 % rifapentine excrete unchanged urine . The microbiologically active metabolite contribute 40 % overall activity drug . The MIC rifapentine M. tuberculosis 0.05 μg/mL ( 0.25 μg/mL 25-desacetyl rifapentine ) . Single-dose rifapentine PK parameter similar healthy female male . Clinical Trials Rifapentine The TBTC perform phase 2 study assess antimicrobial safety efficacy daily rifapentine administer isoniazid , pyrazinamide , ethambutol pulmonary TB treatment . In Study 29 , adult ( n = 531 ) sputum-smear-positive pulmonary TB randomize receive rifapentine 10 mg/kg/dose rifampin 10 mg/kg/dose without food , 5 day per week 8 week , isoniazid , pyrazinamide , ethambutol . This study show significant difference antimicrobial activity regimen , base surrogate marker culture status completion intensive phase ( culture conversion solid medium : rifampin group , 83 % ; rifapentine group , 86 % ) ( culture conversion liquid medium : rifampin group , 65 % ; rifapentine group , 68 % ) . The rifapentine regimen well tolerate , similar proportion participant group discontinue assigned treatment overall ( rifampin group , 16 % ; rifapentine group , 15 % ) toxicity ( rifampin group , 1.2 % ; rifapentine group , 1.5 % ) . There difference proportion participant treatment group serious adverse event relate study treatment ( rifampin group , 0.4 % ; rifapentine group , 1.1 % ) type severity adverse event group . The investigator conclude rifapentine regimen give empty stomach 5 days/week 8 week safe well tolerate significantly active rifampin-based therapy . A subsequent dose-ranging study determine optimal dose daily rifapentine first 8 week TB treatment perform TBTC . In Study 29X , adult ( n = 331 ) sputum-smear-positive pulmonary TB randomize receive rifampin ( 10 mg/kg/dose ) rifapentine ( 10 , 15 , 20 mg/kg/dose ; maximum dose , 1500 mg ) give high fat meal daily ( 7 day per week ) 8 week , addition isoniazid , pyrazinamide , ethambutol . At completion intensive phase , negative culture solid medium note 52 64 subject rifampin group ( 81 % ) ; 62 67 subject rifapentine 10 mg/kg group ( 93 % ; significant ) ; 59 66 subject rifapentine 15 mg/kg group ( 89 % ; significant ) ; 54 57 subject rifapentine 20 mg/kg group ( 95 % ; P ≤ .05 ) . Negative culture liquid medium modify intention-to-treat analysis group occur 36 64 subject rifampin group ( 56 % ) ; 50 67 subject rifapentine 10 mg/kg group ( 75 % ; P ≤ .04 ) ; 46 66 subject rifapentine 15 mg/kg group ( 70 % ; significant ) ; 47 57 subject rifapentine 20 mg/kg group ( 83 % ; P ≤ .01 ) . High-dose daily rifapentine combination standard anti-TB drug well tolerate highly active surrogate bacteriologic test . In treatment trial 29 29X , population PK property rifapentine characterize 415 participant . Rifapentine oral clearance significantly change weight . Rifapentine bioavailability decrease great rifapentine dose increase exposure less dose-proportional . Median exposure steady state rifapentine AUC0-24 292 , 474 , 579 μg*h/mL , respectively , 600 , 900 , 1200 mg daily dos . Because rifapentine clearance weight-dependent , level rifapentine treatment dose ( , mg rather mg/kg dose ) recommend adult . Rifapentine 1200 mg daily incorporate Study 31 treatment trial protocol . Because food take rifapentine study dose significantly increase rifapentine exposure , recommend Study 31 meal take prior rifapentine study dos . An important knowledge gap TB clinical trial efficiently economically assess new drug efficacy , biomarkers commonly use phase 2 trial vary success predict drug efficacy phase 3 trial . However , optimal use drug achieve population pharmacokinetic-pharmacodynamic ( PK/PD ) study combine pharmacokinetic property drug efficacy outcomes treatment . In TBTC Study 29-29X PK/PD , relation rifapentine exposure response time conversion sputum culture establish . In analysis , efficacy rifapentine exposure-dependent . Using maximum inhibitory effect ( Emax ) time-to-event model , highly significant rifapentine exposure-response relationship observe . With rifapentine AUC0-24 &gt; 350 μg*h/mL , percentage participant culture conversion sputum positive negative liquid medium 2 month rifapentine treatment model 74 % rifapentine AUC0-24 &lt; 300 μg*h/mL ( `` low rifapentine AUC ) 55 % . In summary , adequately high rifapentine exposure result good response , large cavity size poorer response . The TBTC Study 31 phase 3 , multicenter , international , randomize , control , open-label , 3-arm , non-inferiority trial enroll newly diagnose , previously untreated participant pulmonary TB . Two investigational regimen evaluate determine duration treatment drug-susceptible pulmonary TB reduce compare standard rifampin-containing six month treatment regimen . In one investigational arm , efficacy single substitution rifapentine rifampin 17 week regimen assess . The second investigational arm evaluate rifapentine-containing regimen also substitute moxifloxacin ethambutol continue moxifloxacin 17 week . The Study 31 primary efficacy endpoint TB disease-free survival 12 month study treatment assignment . In addition , time culture conversion assess . The primary safety endpoint proportion participant grade 3 high adverse event study drug treatment . This PK/PD Study component TBTC Study 31 . MOXIFLOXACIN Moxifloxacin Pharmacokinetics Moxifloxacin fluoroquinolone potent activity M. tuberculosis . Moxifloxacin well absorbed 90 % bioavailability . The PK parameter linear 50 800 mg ( single dose ) ≤ 600 mg ( daily dose ) 10 day ) . Steady state reach within 3 day . The mean ± SD Cmax AUC0-24 value steady state 400-mg once-daily dosage regimen 4.5 ± 0.5 μg/mL 48 ± 3 μg*h/mL . Trough plasma concentration steady state ( 400 mg daily ) 1.0 ± 0.1 μg/L . The time Cmax ( Tmax ) 1 3 hour . The mean plasma half-life 12 ± 3 hour . Coadministration food may slightly prolong Tmax reduce Cmax 16 % , effect clinically important . Administration yogurt high fat meal significantly affect AUC . However , coadministered aluminum- , magnesium- , calcium-containing antacid markedly reduce oral bioavailability fluoroquinolones . Moxifloxacin 50 % bound plasma protein . It widely distribute , tissue concentration excess plasma level . Moxifloxacin metabolize glucuronide sulfate conjugation . The sulfate conjugate ( M1 ) account 38 % oral dose excrete feces ; 14 % oral dose convert glucuronide conjugate ( M2 ) excrete urine . Peak plasma level M1 &lt; 10 % M2 40 % parent drug level . Much ( 45 % ) oral dose excrete parent drug 51 % know metabolite . Based population PK modeling , moxifloxacin AUC0-24 participant TB predict acceptable accuracy use limited sampling strategy . Rifampin induce activity phase 2 enzyme glucuronosyltransferase sulfotransferase . In PK drug interaction rifampin moxifloxacin , moxifloxacin AUC0-24 decrease 27 % ( ratio geometric mean , 73 [ 90 % CI , 64 84 ] ) coadministration rifampin dose 600 mg daily . In PK interaction study 19 participant tuberculosis , moxifloxacin AUC0-24 Cmax decrease moxifloxacin administer daily rifampin isoniazid compare moxifloxacin alone ( ratio geometric mean AUC0-24 , 0.69 [ 90 % CI , 0.65 0.74 ] ; Cmax , 0.68 [ 90 % CI , 0.64 0.73 ] ) . With rifapentine dose 3 time per week PK interaction study healthy volunteer , moxifloxacin AUC0-inf decrease 17 % . In RIFAQUIN PK study 28 adult pulmonary tuberculosis treat continuation-phase regimen 400 mg moxifloxacin 900 mg rifapentine twice weekly , 400 mg moxifloxacin 1200 mg rifapentine weekly , median moxifloxacin AUC0-inf rifapentine treatment weekly decrease 9 % twice weekly decrease 11 % . These PK drug interaction study indicate moxifloxacin AUC0-inf decrease increased frequency rifamycin dosing ( weekly daily dose ) . The magnitude reduction moxifloxacin concentration give rifapentine dose 1200 mg daily unknown . Moxifloxacin Tuberculosis Treatment Two phase 2 TB clinical trial show substitution moxifloxacin ethambutol intensive phase pulmonary TB treatment increase bactericidal activity multi-drug , intensive-phase regimen , assess sputum culture conversion negative 2 month treatment . In another study , treatment weekly regimen rifapentine moxifloxacin continuation phase therapy ( total TB treatment 6 month ) inferior daily isoniazid plus rifampin ; efficacy rifapentine plus moxifloxacin trial important once-weekly rifapentine isoniazid ( instead moxifloxacin ) associate high frequency relapse treatment failure . In REMox phase 3 trial , randomize double-blind trial test non-inferiority seventeen week isoniazid , rifampicin moxifloxacin supplement pyrazinamide first eight week ( INH-arm ) compare standard 6 month rifampin base regimen tuberculosis , number participant classify favorable control regimen per protocol 467 ( 92 % ) INH-arm 436 ( 85 % ) difference 6.1 % ( 97.5 % CI 1.7-10.5 ) . In trial , moxifloxacin contain regimen bactericidal control regimen , insufficient activity permit rifampin-moxifloxacin regimen shorten 4 month . The relationship moxifloxacin concentration TB treatment outcomes moxifloxacin give part high-dose rifapentine-based multidrug treatment drug-sensitive TB unknown . Further , target exposure moxifloxacin treatment TB define . Rationale Intensive `` Late '' PK Samplings Rifapentine Two Different Occasions Autoinduction describe previously daily dose rifamycins , include rifampin rifapentine . With autoinduction metabolize enzyme transporter , bioavailability clearance theoretically affect . In population PK model healthy volunteer , rifapentine clearance appear time-dependent , whereas time less significant effect bioavailability . In addition , clear relationship dose clearance , dose effect time clearance . Further prior study , time maximal autoinduction daily dose could estimate increase clearance see final PK sample day 14 day dose . PK sample longer dose interval require determine time course autoinduction change exposure time repeat dose . Information PK study need fill knowledge gap , model population PK model parameter without bias satisfactory precision ( relative standard error &lt; 20 % ) . Reiterated simulation re-estimations ( `` sse '' ) rifapentine data Study 29-29X perform ass optimal Study 31 PK/PD design : ( 1 ) between-subject variability ( BSV ) precision population PK parameter , ( 2 ) longitudinal component rifapentine clearance autoinduction . Uncertainty parameter estimate ( RSE ) &lt; 10 % consider acceptable population PK parameter &lt; 20 % parameter describe autoinduction . These simulation indicate parameter describe rifapentine auto-induction , important multiple PK sampling obtain , PK sample occasion time-balanced . If perform , uncertainty longitudinal change clearance substantially increase , i.e . protocol design one initial PK sample able identify longitudinal change clearance satisfactory precision , lead high uncertainty parameter estimate . A parsimonious design efficiently assess longitudinal change clearance adequate certainty limited cost , include follow feature : ( ) minimum 60 participant ; ( ii ) intensive PK sampling ( 6 optimal samples/participant ( time = 0.5 , 3 , 6 , 9 , 12 , 24 hour ) least one occasion ; ( iii ) late sample 2 3 PK sample another , later occasion separate minimum 14 day . In summary , PK/PD Study valuable , allow robust development population PK model parameter rifapentine moxifloxacin presence high-dose rifapentine , evaluate PK/PD relationship study drug efficacy outcome .</detailed_description>
	<mesh_term>Tuberculosis</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin B 6</mesh_term>
	<mesh_term>Pyridoxal</mesh_term>
	<mesh_term>Pyridoxine</mesh_term>
	<mesh_term>Rifampin</mesh_term>
	<mesh_term>Rifapentine</mesh_term>
	<mesh_term>Fluoroquinolones</mesh_term>
	<mesh_term>Isoniazid</mesh_term>
	<mesh_term>Pyrazinamide</mesh_term>
	<mesh_term>Ethambutol</mesh_term>
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>Vitamin B Complex</mesh_term>
	<mesh_term>Norgestimate , ethinyl estradiol drug combination</mesh_term>
	<criteria>Age 18 year great Enrolled TBTC Study 31 Randomized receive one rifapentine treatment regimen . Willingness sample 6 time 1 PK sample session 2 3 time another PK sample session outpatient clinic , clinical research center , hospital . Written informed consent give Study 31 PK/PD study Hematocrit &lt; 25 % recent value , measure within 30 day PK/PD study enrollment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>